Biologics are not Natural Monopolies

Recently, several physicians and health policy analysts took to the Health Affairs blog to propose what was, to anyone who has been following biosimilars for the last decade or more, a surprising and concerning idea: that biosimilars should be abandoned.

Costs of the Green New Deal

With the government reopened (at least for now), Speaker Nancy Pelosi is poised to begin advancing her party’s policy agenda. High on the list will be the loosely-defined Green New Deal, a federal spending program that will cost $2 trillion, $5.7 trillion, or more, and move the electric power sector to complete reliance on renewable energy sources.

Happy Birthday, FDA Tobacco Plan!

Just over a year ago, the Food and Drug Administration (FDA) announced a bold new plan to reduce nicotine in cigarettes to non-addictive levels and encourage the development of non-combustible nicotine products. Key to the FDA’s approach is an acknowledgement of both the continuum of risks associated with various nicotine delivery mechanisms and the opportunity for innovative products to reduce the health risks associated with tobacco consumption